Literature DB >> 19251840

Th2 cytokine-induced upregulation of 11beta-hydroxysteroid dehydrogenase-1 facilitates glucocorticoid suppression of proasthmatic airway smooth muscle function.

Aihua Hu1, Sumbul Fatma, Jing Cao, Judith S Grunstein, Gustavo Nino, Yael Grumbach, Michael M Grunstein.   

Abstract

The anti-inflammatory actions of endogenous glucocorticoids (GCs) are regulated by the activities of the GC-activating and -inactivating enzymes, 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 and 11beta-HSD2, respectively, that catalyze the interconversion of the inert GC, cortisone, and its bioactive derivative, cortisol. Proinflammatory cytokines regulate 11beta-HSD1 expression in various cell types and thereby modulate the bioavailability of cortisol to the glucocorticoid receptor (GR). Since endogenous GCs reportedly attenuate the airway asthmatic response to allergen exposure, we investigated whether airway smooth muscle (ASM) exhibits cytokine-induced changes in 11beta-HSD1 expression that enable the ASM to regulate its own bioavailability of GC and, accordingly, the protective effect of GR signaling on airway function under proasthmatic conditions. Human ASM cells exposed to the primary proasthmatic T helper type 2 (Th2) cytokine, IL-13, exhibited upregulated expression of 11beta-HSD1, an effect that was attributed to activation of the transcription factor, AP-1, coupled to MAPK signaling via the ERK1/2 and JNK pathways. The induction of 11beta-HSD1 expression and its oxoreductase activity by IL-13 (also IL-4) served to amplify the conversion of cortisone to cortisol by the cytokine-exposed ASM and, hence, heighten GR-mediated transcriptional activation. Extended studies demonstrated that this amplified 11beta-HSD1-dependent GC activation enabled physiologically relevant concentrations of cortisone to exert enhanced protection of ASM tissues from the proasthmatic effects of IL-13 on ASM constrictor and relaxation responsiveness. Collectively, these novel findings identify a Th2 cytokine-driven homeostatic feedback mechanism in ASM that enhances its responsiveness to endogenous GCs by upregulating 11beta-HSD1 activity, thereby curtailing the adverse effects of the proasthmatic cytokine on airway function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19251840      PMCID: PMC2681349          DOI: 10.1152/ajplung.90572.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  57 in total

1.  IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle.

Authors:  M M Grunstein; H Hakonarson; J Leiter; M Chen; R Whelan; J S Grunstein; S Chuang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-03       Impact factor: 5.464

Review 2.  Effects of corticosteroids on structural cells in asthma and chronic obstructive pulmonary disease.

Authors:  Reynold A Panettieri
Journal:  Proc Am Thorac Soc       Date:  2004

3.  Modulation of glucocorticoid receptor expression in human bronchial epithelial cell lines by IL-1 beta, TNF-alpha and LPS.

Authors:  M M Verheggen; P T van Hal; P W Adriaansen-Soeting; B J Goense; H C Hoogsteden; A O Brinkmann; M A Versnel
Journal:  Eur Respir J       Date:  1996-10       Impact factor: 16.671

4.  Abnormalities in airway smooth muscle in fatal asthma.

Authors:  T R Bai
Journal:  Am Rev Respir Dis       Date:  1990-03

5.  Effect of dexamethasone and endogenous corticosterone on airway hyperresponsiveness and eosinophilia in the mouse.

Authors:  J J De Bie; E M Hessel; I Van Ark; B Van Esch; G Hofman; F P Nijkamp; A J Van Oosterhout
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  The expression of 11 beta-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities.

Authors:  Tian Y Zhang; Xiaohong Ding; Raymond A Daynes
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

7.  A novel action of IL-13: induction of diminished monocyte glucocorticoid receptor-binding affinity.

Authors:  J D Spahn; S J Szefler; W Surs; D E Doherty; S R Nimmagadda; D Y Leung
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

8.  Dehydroepiandrosterone and its 7-hydroxylated metabolites do not interfere with the transactivation and cellular trafficking of the glucocorticoid receptor.

Authors:  Caroline Muller; Françoise Cluzeaud; Gregory M Pinon; Marie-Edith Rafestin-Oblin; Robert Morfin
Journal:  J Steroid Biochem Mol Biol       Date:  2004-12-19       Impact factor: 4.292

9.  Late asthmatic response to Ascaris antigen challenge in dogs treated with metyrapone.

Authors:  H Sasaki; M Yanai; S Shimura; H Okayama; T Aikawa; T Sasaki; T Takishima
Journal:  Am Rev Respir Dis       Date:  1987-12

10.  A comparison of beta-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle.

Authors:  T R Bai; J C Mak; P J Barnes
Journal:  Am J Respir Cell Mol Biol       Date:  1992-06       Impact factor: 6.914

View more
  10 in total

1.  IL-13-induced changes in endogenous glucocorticoid metabolism in the lung regulate the proasthmatic response.

Authors:  Maureen B Josephson; Junfang Jiao; Shuyun Xu; Aihua Hu; Chinmay Paranjape; Judith S Grunstein; Yael Grumbach; Gustavo Nino; Portia A Kreiger; Joseph McDonough; Michael M Grunstein
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-06       Impact factor: 5.464

Review 2.  An integrated mechanism of pediatric pseudotumor cerebri syndrome: evidence of bioenergetic and hormonal regulation of cerebrospinal fluid dynamics.

Authors:  Claire A Sheldon; Young Joon Kwon; Grant T Liu; Shana E McCormack
Journal:  Pediatr Res       Date:  2014-11-24       Impact factor: 3.756

3.  Elevated hepatic 11β-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia.

Authors:  Ananda Chapagain; Paul W Caton; Julius Kieswich; Petros Andrikopoulos; Nanda Nayuni; Jamie H Long; Steven M Harwood; Scott P Webster; Martin J Raftery; Christoph Thiemermann; Brian R Walker; Jonathan R Seckl; Roger Corder; Muhammad Magdi Yaqoob
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-25       Impact factor: 11.205

Review 4.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

5.  Constitutively active signaling by the G protein βγ-subunit mediates intrinsically increased phosphodiesterase-4 activity in human asthmatic airway smooth muscle cells.

Authors:  Aihua Hu; Barry L Diener; Maureen B Josephson; Michael M Grunstein
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

6.  IL-4 type 1 receptor signaling up-regulates KCNN4 expression, and increases the KCa3.1 current and its contribution to migration of alternative-activated microglia.

Authors:  Roger Ferreira; Starlee Lively; Lyanne C Schlichter
Journal:  Front Cell Neurosci       Date:  2014-07-01       Impact factor: 5.505

7.  11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes.

Authors:  Kesong Peng; Yong Pan; Jieli Li; Zia Khan; Mendi Fan; Haimin Yin; Chao Tong; Yunjie Zhao; Guang Liang; Chao Zheng
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

8.  Interleukin-13 signaling and its role in asthma.

Authors:  Efren L Rael; Richard F Lockey
Journal:  World Allergy Organ J       Date:  2011-03       Impact factor: 4.084

9.  Pro-asthmatic cytokines regulate unliganded and ligand-dependent glucocorticoid receptor signaling in airway smooth muscle.

Authors:  Aihua Hu; Maureen B Josephson; Barry L Diener; Gustavo Nino; Shuyun Xu; Chinmay Paranjape; Jordan S Orange; Michael M Grunstein
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

Review 10.  Mechanisms of Glucocorticoid Action in Chronic Rhinosinusitis.

Authors:  Sang Hag Lee
Journal:  Allergy Asthma Immunol Res       Date:  2015-05-20       Impact factor: 5.764

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.